PET PET
  • My Account
  • Subscribe
Become a Friend Donate
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • About Us
    • People
    • Press Office
    • Our History
  • Get Involved
    • Become a Friend of PET
    • Volunteer
    • Campaigns
    • Writing Scheme
    • Partnership and Sponsorship
    • Advertise with Us
  • Donate
    • Become a Friend of PET
  • BioNews
    • News
    • Comment
    • Reviews
    • Elsewhere
    • Topics
    • Glossary
    • Newsletters
  • Events
    • Upcoming Events
    • Previous Events
  • Engagement
    • Policy and Projects
      • Resources
    • Education
  • Jobs & Opportunities
  • Contact Us
  • My Account
  • Subscribe
  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements
PETBioNewsCommentMitochondrial replacement therapies in Mexico and the USA - and the FDA

BioNews

Mitochondrial replacement therapies in Mexico and the USA - and the FDA

Published 11 September 2017 posted in Comment and appears in BioNews 915

Author

Dr César Palacios-González

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.

Almost a year after the first live birth of a baby following a mitochondrial replacement technique procedure, the US Food and Drug Administration has sent a very strongly-worded letter to the scientist and team responsible for the event...

Almost a year after the first live birth of a baby following a mitochondrial replacement technique (MRT) procedure (see BioNews 871), the US Food and Drug Administration has sent a very strongly-worded letter to the scientist and team responsible for the event.

The FDA's letter not only lists many of the violations – although it clearly states that it is not an all-inclusive list – that according to them Dr John Zhang and his team at the New Hope Fertility Centre in New York City have incurred, but also points out that Dr Zhang had continued to market MRTs in the USA, through private company Darwin Life Inc. and/or the New Hope Fertility Centre, as a way to 'to prevent the transmission of mitochondrial disease and to treat infertility', even when he had agreed not to do so. At this time Darwin Life website appears to have been pulled down. It is unclear what other actions the FDA will take following its letter. Though surprising, this is just the latest episode of a story that has been fraught with ethical and legal questions.

Before I explain why this development is important for MRTs in the US, let's briefly recap on what MRTs are. MRTs are new reproductive technologies that could help women at risk of passing mitochondrial DNA diseases to have genetically related children absent such conditions. One technique uses eggs and the other uses single cell human embryos (click here for a video explaining the difference). These techniques raise a number of important ethical questions, for example: should the egg donation be anonymous, are there moral differences between the two techniques that have been proposed, how should they be introduced into the clinic, are there important differences between the nuclear genome and the mitochondrial genome? But the ethical and legal questions that have haunted the birth last year relate more to how the experiment was carried out.

In September last year New Scientist broke the news about the first live birth following an MRT. One characteristic that stood out immediately was that, according to what was implied in the publication, the experiment happened in the city of Guadalajara, Mexico. This was of interest because the lead researcher Dr Zhang is a US-based fertility doctor. At that time Dr Zhang was quoted as saying that they went to Mexico because there there are 'no rules'.

My first reaction was that this was bad news for Mexico (see BioNews 871), given that at that time a very restrictive amendment to the General Health Law, a federal level legislation, was being discussed in Congress. My second reaction was of incredulity: are there really no laws in Mexico that apply to MRTs? María de Jesús Medina-Arellano and I wrote an academic paper where we explored the legal status of MRTs in Mexico. We concluded that, according to our interpretation of the law and the information that was publicly available at that point, Dr Zhang et al broke federal health regulations. For us it was important to write the paper because there we showed that there are indeed regulations in Mexico that apply directly to MRTs at the present time.

A month or so later, Dr Zhang and colleagues published a case report in Reproductive BioMedicine Online detailing their experiment. Their paper was accompanied with a critical editorial that contained a key piece of information for the legal assessment of this procedure: 'In the case described here, the MRT embryos were generated in New York through privately funded research, but the therapeutic part of the procedure – that is, transfer of the embryo to the patient – was done at an affiliated clinic in Mexico, thereby technically circumventing the federal statute.'

This, in the end, means that our legal assessment regarding this particular case was incorrect. Nevertheless, it is interesting that during media interviews Dr Alejandro Chavez-Badiola, medical director and founder of the New Hope Fertility Centre Mexico, did not previously clarify that the MRT procedure happened in the USA – even after a Mexican reporter for the programme Despierta con Loret explicitly said in front of Dr Chavez-Badiola that the experiment was carried out in Mexico.

Now, answering the question 'what does the FDA's letter mean for the clinical use of MRTs in the USA' seems to be straightforward at this point. First, a provision in a congressional spending bill bars the FDA from evaluating 'research in which a human embryo is intentionally created or modified to include heritable genetic modification', which according to them includes MRTs. Second, the FDA considers that MRT experiments fall within their rule and they will not turn a blind eye to them, even if the egg or zygote is intended for export. At this point we will have to wait and see if Dr Zhang decides to move all his MRT operation outside of the USA, or if this was a very short-lived stint.


Dr César Palacios-González is speaking in the session 'The Wild East and the Worried West: Pioneers or Outlaws?' at the Progress Educational Trust's upcoming public conference 'Crossing Frontiers: Moving the Boundaries of Human Reproduction'.

The conference is taking place in London on Friday 8 December 2017. Full details - including sessions, speakers and how to book your place - can be found here.

Related Articles

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
24 May 2019 • 2 minutes read

DNA study may have implications for mitochondrial donation

by Jenny Sharpe

Mitochondria are not as interchangeable as originally thought, with implications for the selection of donors for mitochondrial donation...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
28 September 2018 • 3 minutes read

Genome editing works in mitochondrial DNA for first time

by Dr Jamie Heather

Two research groups have, for the first time, used genome editing to successfully treat mitochondrial disease in animals...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
29 January 2018 • 5 minutes read

The wild east and the worried west: pioneers or outlaws?

by Dr Danielle Griffiths

'The Wild East and the Worried West: Pioneers or Outlaws?’ was the third session of the Progress Educational Trust's (PET) Annual Conference 'Crossing Frontiers: Moving the Boundaries of Human Reproduction'...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
News
4 October 2017 • 2 minutes read

Call for Australia to allow mitochondrial donation techniques

by Jenny Sharpe

A campaign has been launched in Australia to overturn laws preventing couples from accessing mitochondrial donation...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
31 August 2017 • 3 minutes read

FDA reprimands US doctor trying to commercialise MRT

by Georgia Everett

The Food and Drug Administration has warned a US fertility doctor to stop marketing mitochondrial replacement therapy — a technique involving the creation of an embryo with DNA from three people...

Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
CC0 1.0
Image by Alan Handyside via the Wellcome Collection. Depicts a human egg soon after fertilisation, with the two parental pronuclei clearly visible.
News
4 July 2017 • 2 minutes read

Controversial doctor to use MRT technique for over 40s fertility

by Shaoni Bhattacharya

The fertility doctor who led the team which produced the world's first baby through mitochondrial replacement therapy is now looking to use the same technique in a commercial venture...

Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the output from a DNA sequencing machine.
CC BY 4.0
Image by Peter Artymiuk via the Wellcome Collection. Depicts the shadow of a DNA double helix, on a background that shows the fluorescent banding of the sequencing output from an automated DNA sequencing machine.
Comment
25 April 2017 • 4 minutes read

Mitochondrial replacement techniques, Mexico and the legal unknowns

by Dr César Palacios-González

It is not every day that we can examine the details of the first use of a new reproductive technology. But the first live birth of a baby following the use of a mitochondrial replacement technique (MRT) in IVF last year gives a window into just this. The

Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family (from Greek and Roman mythology) entwined in coils of DNA.
Image by Bill Sanderson via the Wellcome Collection, © Wellcome Trust Ltd 1990. Depicts Laocoön and his family entwined in coils of DNA (based on the figure of Laocoön from Greek and Roman mythology).
Comment
10 October 2016 • 5 minutes read

The Mexican mitochondrial fiasco

by Dr César Palacios-González

Dr John Zhang's team have opened a new door in terms of reproductive possibilities, but they may very well be instrumental in closing the assisted reproductive door for many people in Mexico...

Leave a Reply Cancel reply

You must be logged in to post a comment.

« Men, delayed childbearing and age-related fertility decline

Data-Label The UK's Leading Supplier Of Medical Labels & Asset Labels

RetiringDentist.co.uk The UK's Leading M&A Company.

Find out how you can advertise here
easyfundraising
amazon

This month in BioNews

  • Popular
  • Recent
25 July 2022 • 4 minutes read

Was the Women's Health Strategy worth the wait?

25 July 2022 • 5 minutes read

200 Years of Mendel: From Peas to Personalised Medicine

18 July 2022 • 5 minutes read

The birth of genetics: celebrating 200 years of Mendel

15 July 2022 • 2 minutes read

FILM: Prioritising Patient Safety – How to Minimise Risk in Fertility Treatment

11 July 2022 • 6 minutes read

Dutch Embryos Act under revision

1 August 2022 • 4 minutes read

Women's Health Strategy plans reflect rising needs of same-sex female couples

25 July 2022 • 4 minutes read

Was the Women's Health Strategy worth the wait?

25 July 2022 • 4 minutes read

Why the UK should extend the 14-day rule to 28 days

25 July 2022 • 5 minutes read

200 Years of Mendel: From Peas to Personalised Medicine

18 July 2022 • 5 minutes read

The birth of genetics: celebrating 200 years of Mendel

Subscribe to BioNews and other PET updates for free.

Subscribe
  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856

Subscribe to BioNews and other PET updates for free.

Subscribe
PET PET

PET is an independent charity that improves choices for people affected by infertility and genetic conditions.

  • Twitter
  • Facebook
  • Instagram
  • LinkedIn
  • YouTube
  • RSS
Wellcome
Website redevelopment supported by Wellcome.

Navigation

  • About Us
  • Get Involved
  • Donate
  • BioNews
  • Events
  • Engagement
  • Jobs & Opportunities
  • Contact Us

BioNews

  • News
  • Comment
  • Reviews
  • Elsewhere
  • Topics
  • Glossary
  • Newsletters

Other

  • My Account
  • Subscribe

Website by Impact Media Impact Media

  • Privacy Statement
  • Advertising Policy
  • Thanks and Acknowledgements

© 1992 - 2022 Progress Educational Trust. All rights reserved.

Limited company registered in England and Wales no 07405980 • Registered charity no 1139856